Netherlands· NL-23723519d5cc
Segluromet 2,5 mg/1000 mg filmomhulde tabletten
A metformin and ertugliflozin product containing ertugliflozine-l-pyroglutaminezuur + metforminehydrochloride, registered in Netherlands by Merck Sharp & Dohme B.V.. The same ATC class is registered in 8 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Metformin and ertugliflozin is registered in 8 of 19 countries.
Countries holding a registration under ATC A10BD23 (metformin and ertugliflozin), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 5 of them publish a price we can compare per daily dose
Metformin and ertugliflozin · ATC A10BD23
8 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- ERTUGLIFLOZINE-L-PYROGLUTAMINEZUUR + METFORMINEHYDROCHLORIDE
- Manufacturer
- Merck Sharp & Dohme B.V.
- Country
- Netherlands (NL)
- ATC code
- A10BD23
- ATC class
- Metformin and ertugliflozin
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/18/1265
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under A10BD23
Metformin and ertugliflozin, as other registers publish it.
- PolandSeglurometMerck Sharp & Dohme B.V.
- PolandSeglurometMerck Sharp & Dohme B.V.
- FinlandSeglurometMerck Sharp & Dohme B.V.
- FinlandSeglurometMerck Sharp & Dohme B.V.
- FinlandSeglurometMerck Sharp & Dohme B.V.
- DenmarkSeglurometMerck Sharp & Dohme B.V.
- DenmarkSeglurometMerck Sharp & Dohme B.V.
- PolandSeglurometMerck Sharp & Dohme B.V.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d48911e7-5887-4427-83c1-151a3e31bbac GET /v1/drugs/d48911e7-5887-4427-83c1-151a3e31bbac?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmomhulde tablet",
"route": "Oraal gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/segluromet-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Metformin and ertugliflozin",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp120629",
"excipients": [
"CARNAUBAWAS (E 903)",
"CELLULOSE, MICROKRISTALLIJN (E 460(i))",
"CROSPOVIDON (E 1202)",
"HYPROLOSE (E 463)",
"HYPROMELLOSE (E 464)",
"IJZEROXIDE ROOD (E 172)",
"MAGNESIUMSTEARAAT (E 470b)",
"NATRIUMLAURILSULFAAT",
"POVIDON K 30 (E 1201)",
"TITAANDIOXIDE (E 171)"
],
"substances": [
"ERTUGLIFLOZINE-L-PYROGLUTAMINEZUUR",
"METFORMINEHYDROCHLORIDE"
],
"leaflet_url": null,
"authorised_at": "2018/03/23",
"procedure_number": "EMEA/H/C/004314",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/18/1265",
"additional_monitoring": "N"
}See everything about metformin and ertugliflozin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.